# Tumor Characterization Using [18F]FDG PET Radiomics in a PD-L1-Positive NSCLC Cohort

**Authors:** Bernadett Erzsébet Kálmán, Agnieszka Bos-Liedke, Dániel Dezső, Ewelina Kaminska, Mateusz Matusewicz, Ferenc Budán, Domokos Mathe, János Girán, Dávid Sipos, Éva Pusztai, Árpád Boronkai, Zsombor Ritter

PMC · DOI: 10.3390/ph19010103 · 2026-01-07

## TL;DR

This study shows that [18F]FDG PET radiomics can help distinguish lung cancer types and predict PD-L1 status and prognosis in patients.

## Contribution

The study identifies novel radiomic features associated with PD-L1 status and prognosis in squamous NSCLC.

## Key findings

- Radiomic features like maximum diameter and metabolic tumor volume differ between squamous and adenocarcinoma subtypes.
- PD-L1-positive squamous tumors show distinct imaging patterns compared to PD-L1-negative tumors.
- Certain radiomic features correlate with NLR-based prognosis in PD-L1-positive patients.

## Abstract

Background: Durvalumab consolidation following radiochemotherapy is now the standard treatment for unresectable stage III non-small cell lung cancer (NSCLC). [18F]FDG PET/CT offers valuable insights not just for staging but also for tumor characterization via radiomics, which can potentially predict histology, immunophenotype, and prognosis. Methods: We conducted a retrospective analysis of [18F]FDG PET/CT scans from stage IIIA–IIIB NSCLC patients treated at the Clinical Centre, University of Pécs. All biopsy samples were classified histologically (squamous vs. adenocarcinoma) and tested for PD-L1. Lung tumors were segmented using MEDISO InterViewTM FUSION software (version 3.12.002.0000). with an SUVmax threshold of four. Imaging features were extracted and compared based on histology, PD-L1 status, and neutrophil-to-lymphocyte ratio (NLR)-based prognosis groups. Statistical analyses were performed with Jamovi (v2.6.44), using Shapiro–Wilk, t-test/ANOVA, Mann–Whitney/Kruskal–Wallis, or Chi-square tests as appropriate. Results: Fifty-six patients were included (38 PD-L1-positive, 18 -negative). Among PD-L1-positive cases, poor versus good NLR prognosis groups differed in maximum diameter (p = 0.046), short-zone emphasis (p = 0.026), and zone-length non-uniformity (p = 0.027). Focusing on PD-L1-positive squamous carcinoma, maximum diameter, metabolic tumor volume, busyness, and coarseness showed significant differences (all p < 0.05). SUVmax, mean SUV, SUVpeak, and complexity were higher in squamous than in adenocarcinoma subtypes. PD-L1-positive and -negative squamous tumors differed in zone percentage (p = 0.039) and long-zone high gray-level emphasis (p = 0.024), while no significant differences were observed among adenocarcinomas. Conclusions: [18F]FDG PET/CT radiomics showed potential for differentiating NSCLC histological subtypes and for identifying PD-L1-associated imaging patterns in squamous cell carcinoma. In addition, certain metabolic features were associated with NLR-based prognostic groups in PD-L1-positive patients.

## Linked entities

- **Chemicals:** [18F]FDG (PubChem CID 68614)
- **Diseases:** non-small cell lung cancer (MONDO:0005233), NSCLC (MONDO:0005233), squamous cell carcinoma (MONDO:0005096), adenocarcinoma (MONDO:0004970)

## Full-text entities

- **Genes:** CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}
- **Diseases:** squamous tumors (MESH:D018307), NSCLC (MESH:D002289), squamous (MESH:D002294), Tumor (MESH:D009369), Lung tumors (MESH:D008175), adenocarcinoma (MESH:D000230)
- **Chemicals:** [18F]FDG (MESH:D019788), Durvalumab (MESH:C000613593)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12844887/full.md

---
Source: https://tomesphere.com/paper/PMC12844887